Switching to bictegravir/ emtricitabine/tenofovir alafenamide plus darunavir/cobicistat in heavily antiretroviralexperienced, virologically suppressed HIV-infected adults receiving complex regimens: 48-week analysis

被引：0

作者：

Podzamczer, D. ^{[1
]}

Imaz, A. ^{[2
]}

Lopez-Lirola, A. ^{[3
]}

Knobel, H. ^{[4
]}

Masia, M. ^{[5
]}

Fanciulli, C. ^{[6
]}

Hernadez, C. ^{[7
]}

Lagarde, M. ^{[8
]}

Gutierrez, A. ^{[9
]}

Curran, A. ^{[10
]}

Morano, L. ^{[11
]}

Montero-Alonso, M. ^{[12
]}

Troya, J. ^{[13
]}

Rigo, R.

Casadella, M. ^{[14
]}

Navarro-Alcaraz, A. ^{[14
]}

Ardila, F.

Parera, M. ^{[14
]}

Bernal, E. ^{[15
]}

Echeverria, P. ^{[16
]}

Estrada, V. ^{[17
]}

Hidalgo-Tenorio, C. ^{[18
]}

Macias, J. ^{[19
]}

Priet, P. ^{[20
]}

Portilla, J. ^{[21
]}

Valencia, E. ^{[22
]}

Vivancos, M. J. ^{[23
]}

Rivero, A.

机构：

[1] Fight Infect Fdn, Badalona, Spain

[2] Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain

[3] Hosp Univ Canarias, San Cristobal la Laguna, Spain

[4] Hosp Univ Gen Elche, Elche, Spain

[5] Hosp Gen Univ Gregorio Maran, Inst Invest Sanitaria Gregorio Maran IiSGM, Ctr Invest Biomed Red Enfermedades Infecc, Madrid, Spain

[6] Hosp Principe Asturias, Alcala De Henares, Spain

[7] Hosp Univ 12 Octubre, Madrid, Spain

[8] Hosp Univ Princesa, Madrid, Spain

[9] Hosp Univ Vall dHebron, Barcelona, Spain

[10] Hosp Univ Alvaro Cunqueiro, Vigo, Spain

[11] Hosp Univ Politecn La Fe, Valencia, Spain

[12] Hosp Univ Infanta Leonor, Madrid, Spain

[13] IrsiCaixa Inst Recerca SIDA, Badalona, Spain

[14] Hosp Univ Reina Sofia, Murcia, Spain

[15] Hosp Badalona Germans Trias & Pujol, Fight Infect Fdn, Badalona, Spain

[16] Hosp Clin San Carlos, Madrid, Spain

[17] Hosp Univ Virgen de Ias Nieves, Granada, Spain

[18] Univ Seville, IBiS,Hosp Univ Virgen de Valme, Inst Biomed Sevilla,Unidad Enfermedades Infecc &, CIBERINFEC,Dept Med,CSIC, Seville, Spain

[19] Hosp Univ Santa Creu & St Pau, Barcelona, Spain

[20] Hosp Gen Univ Alicante, Alicante, Spain

[21] Hosp Univ La Paz, Madrid, Spain

[22] Hosp Univ Ramon y Cajal, Madrid, Spain

[23] Univ Cordoba UCO, Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba IMIBIC, ISCIII CIBER Enfermedades Infecc Inst Salud Carlo, Cordoba, Spain

来源：

HIV MEDICINE | 2023年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

EACS2023:

引用

页码：310 / 311

页数：2

共 50 条

[1] Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
Podzamczer, Daniel
Imaz, Arkaitz
Lopez-Lirola, Ana
Knobel, Hernando
Masia, Mar
Fanciulli, Chiara
Hernandez, Cristina
Lagarde, Maria
Gutierrez, Angela
Curran, Adria
Morano, Luis
Montero-Alonso, Marta
Troya, Jesus
Rigo, Raul
Casadella, Maria
Navarro-Alcaraz, Antonio
Ardila, Fernando
Parera, Mariona
Bernal, Enrique
Echeverria, Patricia
Estrada, Vicente
Hidalgo-Tenorio, Carmen
Macias, Juan
Prieto, Paula
Portilla, Joaquin
Valencia, Eulalia
Vivancos, Maria Jesus
Rivero, Antonio
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (11) : 2696 - 2701
[2] Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat (DRV/c) in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
Podzamczer, D.
Imaz, A.
Lopez Lirola, A.
Knobel, H.
Masia, M.
Berenguer, J.
Hernandez, C.
Lagarde, M.
Gutierrez, A.
Curran, A.
Morano, L.
Montero-Alonso, M.
Troya, J.
Rigo, R.
Casadella, M.
Navarro-Alcaraz, A.
Rivero Roman, A.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 81 - 82
[3] Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Orkin, Chloe
Molina, Jean-Michel
Negredo, Eugenia
Arribas, Jose R.
Gathe, Joseph
Eron, Joseph J.
Van Landuyt, Erika
Lathouwers, Erkki
Hufkens, Veerle
Petrovic, Romana
Vanveggel, Simon
Opsomer, Magda
[J]. LANCET HIV, 2018, 5 (01): : E23 - E34
[4] Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis
Dunn, Keith
Bushen, Jennifer
Luo, Donghan
Cai, Jiyun
Simonson, Richard Bruce
Anderson, David
[J]. HIV MEDICINE, 2023, 24 (03) : 279 - 289
[5] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
Molina, J-M
Gallant, J.
Orkin, C.
Negredo, E.
Bhatti, L.
Gathe, J.
Van Landuyt, E.
Lathouwers, E.
Hufkens, V.
Vanveggel, S.
Opsomer, M.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
[6] Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
Raffi, Francois
Orkin, Chloe
Clarke, Amanda
Slama, Laurence
Gallant, Joel
Daar, Eric
Henry, Keith
Santana-Bagur, Jorge
Stein, David K.
Bellos, Nicholaos
Scarsella, Anthony
Yan, Mingjin
Abram, Michael E.
Cheng, Andrew
Rhee, Martin S.
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (02) : 226 - 231
[7] A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
Huhn, Gregory D.
Tebas, Pablo
Gallant, Joel
Wilkin, Timothy
Cheng, Andrew
Yan, Mingjin
Zhong, Lijie
Callebaut, Christian
Custodio, Joseph M.
Fordyce, Marshall W.
Das, Moupali
McCallister, Scott
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 (02) : 193 - 200
[8] Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials
Avihingsanon, Anchalee
Chetchotisakd, Ploenchan
Kiertiburanakul, Sasisopin
Ratanasuwan, Winai
Siripassorn, Krittaecho
Supparatpinyo, Khuanchai
Martin, Hal
Wang, Hui
Wong, TinHung
Wang, Hsiu Yin
[J]. HIV MEDICINE, 2023, 24 (03) : 290 - 300
[9] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Franco Maggiolo
Giuliano Rizzardini
Jean-Michel Molina
Federico Pulido
Stephane De Wit
Linos Vandekerckhove
Juan Berenguer
Michelle L. D’Antoni
Christiana Blair
Susan K. Chuck
David Piontkowsky
Hal Martin
Richard Haubrich
Ian R. McNicholl
Joel Gallant
[J]. Infectious Diseases and Therapy, 2021, 10 : 775 - 788
[10] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Maggiolo, Franco
Rizzardini, Giuliano
Molina, Jean-Michel
Pulido, Federico
De Wit, Stephane
Vandekerckhove, Linos
Berenguer, Juan
D'Antoni, Michelle L.
Blair, Christiana
Chuck, Susan K.
Piontkowsky, David
Martin, Hal
Haubrich, Richard
McNicholl, Ian R.
Gallant, Joel
[J]. INFECTIOUS DISEASES AND THERAPY, 2021, 10 (02) : 775 - 788

← 1 2 3 4 5 →